1. Home
  2. ADUS vs MNKD Comparison

ADUS vs MNKD Comparison

Compare ADUS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$94.48

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$2.63

Market Cap

793.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
MNKD
Founded
1979
1991
Country
United States
United States
Employees
N/A
592
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
793.6M
IPO Year
2009
2004

Fundamental Metrics

Financial Performance
Metric
ADUS
MNKD
Price
$94.48
$2.63
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$135.40
$8.64
AVG Volume (30 Days)
204.3K
4.8M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
23.40
N/A
EPS
5.22
0.02
Revenue
N/A
$348,966,000.00
Revenue This Year
$9.17
$35.81
Revenue Next Year
$4.64
$11.89
P/E Ratio
$17.66
$128.25
Revenue Growth
N/A
22.23
52 Week Low
$90.89
$2.23
52 Week High
$124.44
$6.51

Technical Indicators

Market Signals
Indicator
ADUS
MNKD
Relative Strength Index (RSI) 40.75 39.85
Support Level N/A $2.52
Resistance Level $118.51 $6.18
Average True Range (ATR) 2.97 0.13
MACD 0.12 0.11
Stochastic Oscillator 37.51 88.89

Price Performance

Historical Comparison
ADUS
MNKD

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: